Perceptive Advisors LLC bought a new position in Collegium Pharmaceutical Inc (NASDAQ:COLL) in the fourth quarter, HoldingsChannel.com reports. The firm bought 445,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,374,000.
Other large investors have also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its position in Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after buying an additional 3,179 shares during the last quarter. Oregon Public Employees Retirement Fund purchased a new stake in Collegium Pharmaceutical in the fourth quarter worth $103,000. State Board of Administration of Florida Retirement System increased its position in Collegium Pharmaceutical by 4.8% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after buying an additional 655 shares during the last quarter. Jefferies Group LLC purchased a new stake in Collegium Pharmaceutical in the third quarter worth $271,000. Finally, Capital Fund Management S.A. purchased a new stake in Collegium Pharmaceutical in the third quarter worth $286,000.
A number of analysts have issued reports on the company. ValuEngine downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, February 12th. Cantor Fitzgerald set a $35.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, March 8th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Finally, BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $29.80.
In related news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, February 15th. The stock was sold at an average price of $14.81, for a total transaction of $370,250.00. Following the completion of the sale, the director now owns 259,430 shares of the company’s stock, valued at $3,842,158.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 13.87% of the stock is currently owned by company insiders.
Shares of NASDAQ COLL opened at $17.59 on Tuesday. The firm has a market capitalization of $565.52 million, a PE ratio of -14.78 and a beta of 0.35. Collegium Pharmaceutical Inc has a fifty-two week low of $13.10 and a fifty-two week high of $28.91. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.26 and a quick ratio of 1.21.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.65. The company had revenue of $73.40 million during the quarter, compared to analysts’ expectations of $72.71 million. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. The firm’s quarterly revenue was up 579.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.54) earnings per share. As a group, equities research analysts predict that Collegium Pharmaceutical Inc will post -0.14 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “445,000 Shares in Collegium Pharmaceutical Inc (COLL) Purchased by Perceptive Advisors LLC” was first reported by Highlight Press and is the sole property of of Highlight Press. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://highlightpress.com/2019/03/19/445000-shares-in-collegium-pharmaceutical-inc-coll-purchased-by-perceptive-advisors-llc.html.
Collegium Pharmaceutical Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Read More: No Load Funds
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical Inc (NASDAQ:COLL).
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.